Literature DB >> 28696534

A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo.

L F D van Vulpen1,2, J Popov-Celeketic2, M E R van Meegeren1,2, K Coeleveld2, J M van Laar2, C E Hack2,3, R E G Schutgens1, S C Mastbergen2, F P J G Lafeber2.   

Abstract

Essentials Targeted treatment for hemophilic arthropathy, still causing significant morbidity, is lacking. This study evaluates the efficacy of a fusion of protein of interleukin(IL)-4 and IL-10. In vitro the fusion protein prevents blood-induced cartilage damage in a dose-dependent manner. In hemophilic mice, the IL4-10 fusion protein ameliorates cartilage damage upon joint bleeding.
SUMMARY: Background Joint damage still causes significant morbidity in hemophilia. It results from synovial inflammation and direct cartilage-degenerating properties of blood components. Interleukin (IL)-4 and IL-10 have been shown to protect cartilage from blood-induced damage. Recently an IL4-10 fusion protein has been developed to combine the function of IL-4 and IL-10 and increase their bioavailability. Objectives In this study we evaluate whether this IL4-10 fusion protein protects against blood-induced joint damage. Methods In vitro, human cartilage explants were exposed to whole blood and simultaneously to a broad concentration range of the IL4-10 fusion protein. Effects on cartilage matrix turnover were compared with the individual cytokines. Moreover, the influence of the fusion protein and its individual components on IL-1β and IL-6 production was investigated. In hemophilia A mice, the effect of intra-articular treatment on synovitis and cartilage damage resulting from joint bleeding was evaluated by histochemistry. Results In vitro, the fusion protein prevented blood-induced cartilage damage in a dose-dependent manner, with equal effectiveness to the combination of the separate cytokines. In whole blood cultures 10 ng mL-1 fusion protein completely blocked the production of IL-1β and IL-6 by monocytes/macrophages. In hemophilic mice, intra-articular injection of IL-4 and IL-10 did not influence synovitis or cartilage degeneration. In contrast, equimolar amounts of the fusion protein attenuated cartilage damage upon repeated joint bleeding, although synovial inflammation was hardly affected. Conclusions Overall, this study shows that the IL4-10 fusion protein prevents blood-induced cartilage damage in vitro and ameliorates cartilage degeneration upon joint bleeding in hemophilic mice.
© 2017 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  hemarthrosis; hemophilia A; investigational; joint diseases; synovitis; therapies

Mesh:

Substances:

Year:  2017        PMID: 28696534     DOI: 10.1111/jth.13778

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Can photobiomodulation associated with implantation of mesenchymal adipose-derived stem cells attenuate the expression of MMPs and decrease degradation of type II collagen in an experimental model of osteoarthritis?

Authors:  Tatiane Garcia Stancker; Stella Souza Vieira; Andrey Jorge Serra; Rafael do Nascimento Lima; Regiane Dos Santos Feliciano; José Antônio Silva; Solange Almeida Dos Santos; Marcia Ataize Dos Santos Vieira; Maíra Cecília Brandão Simões; Ernesto Cesar Leal-Junior; Paulo de Tarso Camillo de Carvalho
Journal:  Lasers Med Sci       Date:  2018-03-08       Impact factor: 3.161

2.  Resolution of inflammation-induced depression requires T lymphocytes and endogenous brain interleukin-10 signaling.

Authors:  Geoffroy Laumet; Jules Daniel Edralin; Angie Chi-An Chiang; Robert Dantzer; Cobi J Heijnen; Annemieke Kavelaars
Journal:  Neuropsychopharmacology       Date:  2018-07-16       Impact factor: 7.853

3.  The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review.

Authors:  E M van Helvoort; E van der Heijden; J A G van Roon; N Eijkelkamp; S C Mastbergen
Journal:  Cartilage       Date:  2022 Apr-Jun       Impact factor: 3.117

4.  An Evidence-Based Systematic Review of Human Knee Post-Traumatic Osteoarthritis (PTOA): Timeline of Clinical Presentation and Disease Markers, Comparison of Knee Joint PTOA Models and Early Disease Implications.

Authors:  Christine M Khella; Rojiar Asgarian; Judith M Horvath; Bernd Rolauffs; Melanie L Hart
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

Review 5.  Post-traumatic knee osteoarthritis; the role of inflammation and hemarthrosis on disease progression.

Authors:  Bob J Evers; Martijn H J Van Den Bosch; Arjen B Blom; Peter M van der Kraan; Sander Koëter; Rogier M Thurlings
Journal:  Front Med (Lausanne)       Date:  2022-08-22

6.  A Translational Study of TNF-Alpha Antagonists as an Adjunctive Therapy for Preventing Hemophilic Arthropathy.

Authors:  Feixu Zhang; Mengyang Xu; Qin Yang; Baolai Hua; Binglan Xia; Zhenyang Lin; Xiao Xiao; Paul E Monahan; Junjiang Sun
Journal:  J Clin Med       Date:  2019-12-27       Impact factor: 4.241

7.  Joint hemorrhage accelerates cartilage degeneration in a rat immobilized knee model.

Authors:  Yasuhito Sogi; Yutaka Yabe; Yoshihiro Hagiwara; Masahiro Tsuchiya; Yoshito Onoda; Takuya Sekiguchi; Nobuyuki Itaya; Shinichiro Yoshida; Toshihisa Yano; Kazuaki Suzuki; Takahiro Onoki; Eiji Itoi
Journal:  BMC Musculoskelet Disord       Date:  2020-11-19       Impact factor: 2.362

8.  On-demand treatment with the iron chelator deferasirox is ineffective in preventing blood-induced joint damage in haemophilic mice.

Authors:  Astrid E Pulles; Lize F D van Vulpen; Katja Coeleveld; Simon C Mastbergen; Roger E G Schutgens; Floris P J G Lafeber
Journal:  Haemophilia       Date:  2021-05-27       Impact factor: 4.287

9.  IL4-10 Fusion Protein Shows DMOAD Activity in a Rat Osteoarthritis Model.

Authors:  E M van Helvoort; H M de Visser; F P J G Lafeber; K Coeleveld; S Versteeg; H H Weinans; J Popov-Celeketic; N Eijkelkamp; S C Mastbergen
Journal:  Cartilage       Date:  2021-06-23       Impact factor: 4.634

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.